[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing

Rhea-AI Filing Summary

Form 144 notice: The filer proposes to sell 20,000 shares of common stock through Merrill Lynch on 10/01/2025 with an aggregate market value of $700,014.67. The issuer has 138,257,550 shares outstanding. The securities to be sold were acquired as compensation in multiple grants between 01/04/2022 and 01/04/2025 totaling 63,232 shares granted across six dated entries. In the past three months the reporting person sold 40,000 shares on four dates (08/13/2025, 08/15/2025, 09/02/2025, 09/12/2025) generating aggregate gross proceeds of $1,024,880.20. The filer attests they have no undisclosed material adverse information and includes the standard Rule 144 representations.

Insights

Securities Analyst

TL;DR: Insider plans a modest sale (20,000 shares) vs. 138M shares outstanding; recent sales total 40,000 shares for $1.02M.

The filing documents a proposed Rule 144 sale through Merrill Lynch of 20,000 common shares valued at $700k, and shows the seller has recently executed 40,000 shares of sales raising about $1.02M. Acquisition history shows all shares were received as compensation across multiple years, indicating these are insider-held, non-purchased shares. For investors, the size of the proposed sale is small relative to total float; however, the recent concentrated selling activity (40,000 shares in two months) is a factual signal of liquidity needs or portfolio rebalancing but the filing provides no explanation.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 formalities; acquisitions were compensation-based and the signer certifies no undisclosed material information.

The form properly lists acquisition dates and nature (compensation) for each lot and aggregates recent dispositions. The representation about material information and the inclusion of broker and proposed sale date meet filing requirements. There is no indication of a 10b5-1 plan date or other trading plan in the remarks, so sales appear to be ad hoc rather than pursuant to a pre-established plan, based solely on the document content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 75 Rockefeller Plz Flr 2 New York NY 10019	20000	700014.67	138257550	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/04/2022	Compensation	Issuer			3485	01/04/2022	Compensation
Common	01/02/2023	Compensation	Issuer			15802	01/02/2023	Compensation
Common	01/04/2023	Compensation	Issuer			12557	01/04/2023	Compensation
Common	01/04/2024	Compensation	Issuer			1167	01/04/2024	Compensation
Common	01/08/2024	Compensation	Issuer			4950	01/08/2024	Compensation
Common	01/04/2025	Compensation	Issuer			27271	01/04/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Hamilton 177 E Colorado Blvd. Ste 700 Pasadena CA 91105	Common	08/13/2025	611	12190.05
James Hamilton 177 E Colorado Blvd. Ste 700 Pasadena CA 91105	Common	08/15/2025	9389	187750.05
James Hamilton 177 E Colorado Blvd. Ste 700 Pasadena CA 91105	Common	09/02/2025	15000	374970.05
James Hamilton 177 E Colorado Blvd. Ste 700 Pasadena CA 91105	Common	09/12/2025	15000	449970.05

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)